> This is a post from Ben Lankeet to the acor list- David
>
>
> Date:Â Â Â Tue, 29 Apr 2008 09:17:37 -0500
> From:Â Â Â Ben <lankheet@FRONTIERNET.NET>
> Subject: NPI-0052
>
> I recently asked Roswell Park about the status of the NPI-0052 trials and
> got the following response:
>
> "We brought your request to the attention of our clinical research
> associates and have learned that the phase I clinical trial of NPI-0052
> has been suspended and, unfortunately, we have no further information
> about it. Perhaps the manufacturer could provide additional information
> for you."
>
> Does anyone have more information on these trials?
>
> Ben
>
Date:Â Â Â Tue, 29 Apr 2008 11:30:31 EDT
From:Â Â Â Gary Takata <GTTakata@AOL.COM>
Subject: Re: NPI-0052
10480 Wateridge Circle,
San Diego, CA 92121
Phone: (858) 587-4090
Fax: (858) 587-4088
Email:
General Information:
info@nereuspharm.com
Research and Development:
randd@nereuspharm.com
Corporate Development:
corpdev@nereuspharm.com
Investor Relations:
ir@nereuspharm.com
Employment:
humanresources@nereuspharm.com
Media Contact:
plord@pnlifesciences.com
Ben,
Nereus Pharmacueticals is the company you need to contact for info re the
NPI-0052 clinical trial. but realize it is a public company so any info they
give
out will have been blessed by thier legal counsel.
gary
from the acor listserv-
-----------------------------
Date:Â Â Â Thu, 15 May 2008 15:15:02 -0500
From:Â Â Â Ben <lankheet@FRONTIERNET.NET>
Subject: New cancer research
The research goes on. Note that NPI-0052 is mentioned. There is a phase 1b
myeloma study going on in San Diego (on NPI-0052).
Ben
Drugs could help body fight cancer
2 hours ago
New drug treatments are being developed that help the body fight cancer by
unleashing the immune system on weakened tumours.
Researchers believe in future they could be used to spare children the harsh
side effects of chemotherapy.
The drugs have the potential to treat a range of different childhood
cancers, including leukaemia, and diseases of the bones, brain and nerves.
US scientists at the University of Texas studied their effects on
laboratory-grown tissue cultures.
The drugs work by making cancer cells more vulnerable to attack by the
immune system's natural killer (NK) cells. At the same time, they cause NK
cells to become better at targeting tumours.
Dr Dean Lee, from the university's MD Anderson Cancer Centre, said:
"Traditional chemotherapy drugs kill any fast-growing cells like cancer, but
they also killed healthy fast-growing cells like hair, bone marrow and
mucous membranes, making the drugs very toxic.
"There's a new class of drugs that takes cells that aren't properly
regulated and makes them behave. In our study, we found that these drugs
make tumour cells more recognisable and vulnerable to natural killer cells."
Dr Lee found that combining NK cells with the drugs produced a potent
combination.
One drug, MS-275, was tested on laboratory-grown tissue cultures of
osteosarcoma, the most common type of malignant bone cancer. The drug
increased the ability of NK cells to target stress signals emitted by the
tumour cells. At the same time it increased the stress signals, making the
cancer more vulnerable to attack.
Two other drugs, Bortezomib and NPI-0052, were found to have similar effects
on leukaemia cells and neuroblastoma, a cancer that affects nerve tissue.
--
Post new comment